Reimbursement authority NICE published draft guidance today giving a green light to the use of Columvi (glofitamab) in ...

The alliance between AbbVie and Calico dates back to 2014, just a year after it was launched by Alphabet's Google unit, when ...

The study of GanLum (KLU156) – a combination of novel drug ganaplacide with established antimalarial lumefantrine – showed ...

FDA Commissioner Marty Makary and Vinay Prasad, director of the Center for Biologics Evaluation and Research (CBER), describe ...

For the Financial Times (FT) Global Pharma & Biotech Summit in London 2025, pharmaphorum is providing coverage courtesy of ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be ...

Trenton M. Johnson is a seasoned project management leader with 27+ years of experience working in the biopharma industry ...

Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by the problem pathogen Escherichia coli looks all but defunct after the two partners halted a phase 3 trial. In a ...

COP27 is in full swing and world leaders are contending with the fact that we will likely not meet the Paris Agreement’s 1.5°C target. The reality is that we will need to focus on limiting a ...

UK start-up George Medicines has brought its triple therapy for high blood pressure over the finish line, with an FDA approval that sets up a launch before the end of this year. Widaplik (previously ...

UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of the year.

The EMA's human medicines committee has said it does not recommend approval of Eli Lilly's anti-amyloid Alzheimer's disease treatment Kisunla, saying its modest benefits don't outweigh its risks. The ...